AMCP Nexus 2025 research posters

Studies on GLP-1 drugs, specialty therapies and more help improve affordability in health care
Click on the poster image to view the full-size version.
Prime Therapeutics (Prime) once again has a robust presence at the Academy of Managed Care Pharmacy (AMCP) Nexus conference from Oct. 27–30, 2025, in National Harbor, Maryland. AMCP is the nation’s leading professional association that aims to help patients get the medications they need at a cost they can afford. This event annually attracts thousands of industry leaders, health care professionals and stakeholders committed to advancing the field. Prime’s teams will present research posters and educational sessions on health outcomes research.  

Three-Year Real-World Adherence and Persistence to Glucagon-Like Peptide-1 Receptor Agonists Among Commercially Insured Adults with Obesity without Diabetes 

This study evaluates adherence and persistence to GLP-1 therapy at the end of a three-year follow-up in a real-world cohort of commerically insured members with obesity and without diabetes.

Trends in Real-World Persistence to Weight Loss Glucagon-Like Peptide-1 Receptor Agonists from 2021 to 2024 Among Commercially Insured Adults without Diabetes

This study earned a platinum award from AMCP.  It evaluates one-year persistence and adherence to high-potency, weight-loss-indicated GLP-1 therapy among commercially insured adults without diabetes, stratified by year of treatment initiation from Jan. 1, 2021 through March 31, 2024. 

Impact of a Medical Claims Automated Glucagon Like Peptide-1 Drugs Prior Authorization Program

This study earned a gold award from AMCP.  It measures the impact of the PBM using a health plan medical claims diagnosis to automate the diabetes GLP-1 prior authorization (PA) process by assessing the percentage of all diabetes FDA-approved GLP-1 claims paid via an automated PA process. 

Validation of Long-term Savings from a Pharmacist-to-Prescriber Telephonic Intervention

This study earned a gold award from AMCP. It determines actualized client savings in the two-year postintervention period for historical HighTouchRx success cases and compares these actualized savings to savings derived by the HighTouchRx annualization process.

Total Cost of Care and Adverse Effects Assessment of Bispecific T-cell Engagers and Chimeric Antigen Receptor T-cell Therapies for Relapsed Refractory Follicular Lymphoma  

This study compares the 12-month total cost of care and adverse events incidence for patients treated with CAR T versus BiTE therapy in relapsed refractory follicular
lymphoma.